SHARx warns PBM transparency may not lower employers’ drug costs
AI Summary- SHARx urges employers to assess total pharmacy costs beyond PBM rebate disclosures.
- $7.3 billion in dispensing revenue exceeded estimated acquisition costs from 2017 through 2022.
- FTC reported affiliated pharmacies received 68% of specialty-drug dispensing revenue in 2023.